Lb Pharmaceuticals (LBRX) Total Liabilities (2024 - 2026)

Lb Pharmaceuticals' Total Liabilities history runs 3 years deep, the most recent figure standing at $14.8 million for Q1 2026.

• In Q1 2026, Total Liabilities fell 85.11% year-over-year to $14.8 million; the TTM figure through Mar 2026 stood at $14.8 million (down 85.11% YoY), while the FY2025 annual figure was $11.6 million, down 15.94% from the prior year.
• Total Liabilities was $14.8 million for Q1 2026 at Lb Pharmaceuticals, up from $11.6 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $99.3 million in Q1 2025 to a low of $10.5 million in Q3 2025.
• Historically, Total Liabilities has averaged $40.3 million across 3 years, with a median of $14.3 million in 2024.
• Biggest YoY gain for Total Liabilities was 15.94% in 2025; the steepest drop was 88.49% in 2025.
• A 3-year view of Total Liabilities shows it stood at $13.8 million in 2024, then decreased by 15.94% to $11.6 million in 2025, then grew by 27.23% to $14.8 million in 2026.
• The last three Total Liabilities figures came in at $14.8 million (Q1 2026), $11.6 million (Q4 2025), and $10.5 million (Q3 2025), per Business Quant data.